About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

Clinicaltrials.gov identifier NCT03944356

Recruitment Status Recruiting

First Posted May 9, 2019

Last update posted February 4, 2021

Study Description

Brief summary:

Adjuvant therapy with dabrafenib plus trametinib in melanoma was approved in 2018 by the EMA (EUropean Medicines Agency). The purpose of this non-interventional study is to assess the usage of adjuvant dabrafenib and trametinib in clinical practice, where the patient population may differ from study population.

  • Condition or Disease:Melanoma
  • Intervention/Treatment: Drug: Dabrafenib and Trametinib
  • Phase: N/A
Detailed Description

Melanoma is a disease of significant metastatic potential if not detected very early. Oncogenic mutations in BRAF (B-Raf proto-oncogene, serine/threonine kinase) are found in approximately 40% of melanomas and result in constitutive activation of the MAPK (Mitogen-Activated Protein Kinase) pathway. Treatment with the BRAF inhibitor dabrafenib plus the MEK (Mitogen-activated protein kinase kinase) inhibitor trametinib showed improved overall survival in patients with unresectable or metastatic BRAF V600E/K-mutant melanoma (COMBI-d and COMBI-v studies). In an adjuvant setting treatment with dabrafenib and trametinib significantly reduced the risk of melanoma recurrence in patients with high-risk, stage III BRAF V600-mutant melanoma, with improvements in OS (Overall Survival), DMFS (Distant Metastasis Free Survival), and FFR (Freedom From Relaps) (COMBI-AD study). Based on these results, adjuvant dabrafenib plus trametinib therapy was approved in 2018 by the EMA. Compared to the metastatic situation, issues of compliance and treatment adherence may be more relevant in adjuvant treatments, as patients are free of disease and potentially cured even without adjuvant treatment. As the routine administration of drugs including dosing, treatment interruptions, and early termination in clinical practice may vary from procedures defined in clinical trials, this study aims to assess the usage of adjuvant dabrafenib and trametinib in the routine clinical setting.

Study Design
  • Study Type: Observational
  • Estimated Enrollment: 250 participants
  • Observational Model: Case-Only
  • Time Perspective: Prospective
  • Official Title: BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients in the Adjuvant Setting: a Non-interventional Observatory Study
  • Actual Study Start Date: July 2019
  • Estimated Primary Completion Date: May 2023
  • Estimated Study Completion Date: July 2023
Outcome Measures
  • Primary Outcome Measures: 1. Median time on treatment [ Time Frame: Date of first dose up to 12 months ]
    Median time on adjuvant dabrafenib + trametinib treatment defined as the interval between start of treatment and permanent discontinuation of treatment.
  • Secondary Outcome Measures: 1. Permanent study drug discontinuation due to any reason [ Time Frame: From date of first treatment until the date of treatment end, assessed up to 12 months ]
    Rate of permanent study drug discontinuation due to any reason.
  • 2. Permanent study drug discontinuation due to adverse drug reactions [ Time Frame: From date of first treatment until the date of treatment end, assessed up to 12 months ]
    Rate of permanent study drug discontinuation due to adverse drug reactions (ADRs).
  • 3. Pyrexia and related symptoms [ Time Frame: From date of first treatment until the date of treatment end, assessed up to 12 months ]
    Occurrence of pyrexia and related symptoms, listing the grade, number of episodes, and time to resolution.
  • 4. Adverse drug reaction management: pyrexia [ Time Frame: From date of first treatment until the date of treatment end, assessed up to 12 months ]
    Type of adverse drug reaction (ADR) management applied for pyrexia and correlation with occurrence/persistence of pyrexia.
  • 5. Adverse drug reactions in Follow-up [ Time Frame: From date of first treatment until the date of treatment end plus 3 months of follow-up, assessed up to 15 months ]
    ADRs persisting/emerging up to 3 months post-treatment.
  • 6. Health-related quality of life [ Time Frame: Over the course of treatment plus 3 months safety follow up, assessed up to 15 months ]
    Assessment of health-related quality of life (HRQoL), measured by the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC-QLQ-C30). The EORTC QLQ-C30 consists of the folowing scales, with each dimension specifying five levels of severity [not at all (level 1), a little (level 2), quite a bit (level 3), very much (level 4)]: functional scales (Physical, Role, Cognitive, Emotional, Social Functioning) symptom scales (Fatigue, Pain and Nausea/Vomiting) single item scales (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties). Additionally the Global Health Status and QoL scales are incorporated, specifying on a scale from 1 (very poor) to 7 (excellent).
  • 7. Relapse free survival [ Time Frame: From date of first treatment until the date of treatment end, assessed up to 12 months ]
    Relapse free survival (RFS) time and rate
  • 8. Distant metastasis free survival time [ Time Frame: From date of first treatment until the date of treatment end, assessed up to 12 months ]
    Distant metastasis free survival (DMFS) time.
  • 9. Distant metastasis free survival rate [ Time Frame: From date of first treatment until the date of treatment end, assessed up to 12 months ]
    Distant metastasis free survival (DMFS) rate.
  • 10. Overall survival time [ Time Frame: From date of first treatment until the date of treatment end, assessed up to 12 months ]
    Overall survival (OS) time.
  • 11. Overall survival rate [ Time Frame: From date of first treatment until the date of treatment end, assessed up to 12 months ]
    Overall survival (OS) rate.
  • 12. Time on treatment and efficacy endpoints [ Time Frame: From date of first treatment until the date of treatment end, assessed up to 12 months ]
    Correlation between time on treatment and efficacy endpoints (RFS, DMFS, OS).
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers:
  • Sampling Method: Non-Probability Sample
  • Study Population: Adult patients with complete surgical resection of histologically confirmed AJCC (8th edition) clinical stage III (IIIA, IIIB, IIIC, IIID) BRAF V600-mutated cutaneous melanoma who are planned to be treated or who already started treatment no longer than 4 weeks prior to study inclusion with dabrafenib and trametinib under routine conditions according to the applying SmPC.
Criteria

Inclusion Criteria:

- Patients with complete surgical resection of histologically confirmed AJCC (American
Joint Committee on Cancer) (8th edition) clinical stage III (IIIA, IIIB, IIIC, IIID)
melanoma, for whom a decision for adjuvant treatment with dabrafenib and trametinib
has been made before entering the study.

- V600E/K mutation-positive cutaneous melanoma

- Adjuvant treatment with combination therapy of Dabrafenib (Tafinlar®) and Trametinib
(Mekinist®) as indicated in the SmPC (Summary of Product Characteristics) and by
prescription, that has been started no longer that 4 weeks before inclusion of the
patient into the study or which will be initiated directly after inclusion

- Age ≥ 18 years

- Signed written informed consent

Exclusion Criteria:

- Lack of basic demographics and staging information

- Current or planned participation within a clinical trial. The participation in a
follow-up phase of a clinical trial without active intervention is allowed.

- Current or planned treatment of another tumor disease except keratoacanthoma, squamous
cell or basal cell carcinoma of the skin

Contacts and Locations
Contacts

Contact: Alexandra Hansen +49 3037026901 alexandra.hansen@eumelareg.org

Locations
Show 39 Study Locations
Sponsors and Collaborators

EuMelaReg gGmbH

More Information
  • Responsible Party: EuMelaReg gGmbH
  • ClinicalTrials.gov Identifier: NCT03944356 History of Changes
  • Other Study ID Numbers: EUMR-18001
  • First Posted: May 9, 2019 Key Record Dates
  • Last Update Posted: February 4, 2021
  • Last Verified: February 2021
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Melanoma